Lantheus Stock Buy Rating Supported by Increased Pylarify Revenue Projections and Updated EPS Estimates

Lantheus (LNTH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tara Bancroft from TD Cowen maintained a Buy rating on the stock and has a $110.00 price target.

Tara Bancroft’s rating is based on the recent updates to the LNTH model, which align with the Q1:25 earnings preview by TD Cowen Biotech. The adjustments made include an increase in Pylarify revenue projections for 2025 and 2026, reflecting the growth trajectory outlined in the company’s guidance and management’s commentary. Additionally, the non-GAAP EPS estimate for the first quarter has been updated to $1.65, while maintaining the price target at $110. These factors collectively support the Buy rating for Lantheus’s stock.